Lenvatinib + Everolimus
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Renal Cell
Conditions
Carcinoma, Renal Cell
Trial Timeline
Jul 1, 2015 → May 29, 2017
NCT ID
NCT02454478About Lenvatinib + Everolimus
Lenvatinib + Everolimus is a phase 1 stage product being developed by Eisai for Carcinoma, Renal Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT02454478. Target conditions include Carcinoma, Renal Cell.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Renal Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03324373 | Phase 1 | Completed |
| NCT03245151 | Phase 1/2 | Completed |
| NCT03173560 | Phase 2 | Completed |
| NCT02915783 | Phase 2 | Completed |
| NCT02454478 | Phase 1 | Completed |
| NCT01136733 | Phase 1/2 | Completed |
Competing Products
20 competing products in Carcinoma, Renal Cell